A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants with Multiple Myeloma

Trial Identifier: D831EC00001
Sponsor: AstraZeneca
Start Date: July 2025
Primary Completion Date: June 2028
Study Completion Date: June 2028
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Duarte, CA, US, 91010
US, CO Denver, CO, US, 80218
US, FL Tampa, FL, US, 33612
US, MO Saint Louis, MO, US, 63110
US, NY New York, NY, US, 10016
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75235
US, TX Houston, TX, US, 77030